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Objective: To investigate if chronic mucus hypersecretion (CMH) can be used as a
marker of asthma in young adults.
Study design and setting: Cross-sectional study of a population sample of young
Danish adults (n ¼ 624, 279 males), aged 19–29 years. Case history, including
tobacco exposure and respiratory symptoms, was obtained by questionnaire.
Pulmonary function, histamine responsiveness, bronchodilator reversibility, skin
test reactivity, and leukocyte count were measured using standard techniques.
Results: The overall prevalence of CMH was 7.7%, 8.4% in females and 6.9% in
males, respectively, of whom more than 70% were current smokers. The presence of
CMH was significantly associated with self-reported asthma, dyspnea at exertion,
number of pack-years, lower FEV1/FVC ratio, and lower BMI. However, no significant
association was found between CMH and the following asthma-related factors:
airway responsiveness to inhaled histamine, bronchodilator reversibility, self-
reported rhinitis or eczema, atopy, FEV1 (%pred), and B-eosinophil count.
Conclusions: CMH is a common finding in young adults, primarily in smokers. CMH
was related to respiratory symptoms suggesting asthma, but no significant
association was observed between CMH and objective signs of asthmatic airway
lability. The present findings therefore may suggest that CMH is likely to be an early
marker of smoking-related lung disease in young adults, instead of a marker of
reversible obstructive lung disease, which may have important implications for the
approach to young people presenting with respiratory symptoms suggesting asthma.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
revsvej 13, DK-2830 Virum, Denmark. Fax: +45 4583 6331.
(C.S. Ulrik).
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Chronic mucus hypersecretion (CMH) is a common
symptom in patients suffering from asthma,1
especially patients with more severe or poorly
controlled disease, and this respiratory symptom is
now considered to be a risk factor for increased
morbidity in patients suffering from asthma.2
Moreover, results of population studies of adults
suggest that the combination of CMH and asthma is
associated with both a steeper decline of lung
function3–5 and excess mortality6 compared with
asthma alone.
In middle aged and older smokers, CMH is
generally considered a symptom of chronic ob-
structive pulmonary disease (COPD) due to its link
to chronic bronchitis. However, it has been a
matter of debate whether CMH is an innocent
bystander or an independent predictor for the
development and prognosis of COPD.7–10
Presently little is known about CMH-associated
morbidity in young adults. Based on our present
knowledge from studies of older adults, the
presence of CMH in adolescents and young adults
may be either a marker for asthmatic airway
inflammation, a risk factor for subsequent devel-
opment of clinically important non-reversible air-
flow limitation, i.e. COPD, or a harmless symptom.
The aim of this population study of young Danish
adults was to investigate whether CMH, in an
epidemiological setting, is a marker of asthma or
may be more closely associated with signs of
smoking-related effects on airway function.Materials and methods
Subjects
Subjects included in the study took part in a
prospective population study of asthma, allergy
and airway hyperresponsiveness initiated in 1986.11
A sample of 983 children and adolescents (mean
age 12 years, range 7–17 years) living in the area
surrounding Rigshospitalet in the city of Copenha-
gen was drawn from the civil registration list, as
described previously.11,12 All subjects in the original
sample (n ¼ 976; seven had died) were invited by
letter to participate in the present third survey of
the sample. Of the 940 eligible subjects (36
subjects lived outside Denmark), 624 (66%) partici-
pated in the study in 1998 (345 females and 279
males) aged 19–29 years; only data from the third
survey were used in this cross-sectional analysis.
Comparison between the 624 participants in thethird survey and the 193 individuals who partici-
pated only in either (or both) of the two previous
surveys of the sample did not reveal any significant
differences with regard to prevalence of asthma,
rhinitis, eczema, airway hyperresponsiveness or
atopy.Questionnaire data
The participants filled in a questionnaire about
respiratory and non-respiratory diseases, active
smoking and passive exposure to smoke, use of
medication, and known or suspected asthma and
allergic disease, including rhinitis and eczema, as
related to themselves, their siblings and parents;
and afterwards, all participants were interviewed
by one person (CSU) in order to check (and if
necessary correct) and add to the information
obtained in the questionnaire.
Participants who reported sputum production
when coughing on most days, during at least 3
months in two successive years were defined as
having CMH.
The questionnaire concerning asthma symptoms
included the following questions:13–16 (1) Does your
breathing ever sound wheezy or whistling? (2) Do
you have attacks of shortness of breath with
wheezing? (3) Do you experience wheezing, chest
tightness, cough, breathlessness with any of the
following: at rest, with exertion, with emotional
stress, with exposure to cold air, with chest
infections or a head cold? (4) Do you experience
wheezing after exposure to: dust, fumes, moulds,
pollen, food, pets or drugs? (5) Have you ever had
attacks of wheezing, shortness of breath or dry
cough at night? Asthma (questionnaire criteria [QC]
asthma) was defined on the basis of positive
responses to at least three of the questions.13–16
Participants who had been hospitalized or observed
and treated by a doctor for asthma were defined as
having doctor-diagnosed asthma (MD asthma).
Current asthma was defined as symptoms of
asthma/episodes of wheezing/treatment for asth-
ma within the preceding 12 months.
All participants reported whether they were
current smokers, ex-smokers or never smokers.
The duration of smoking and the daily tobacco
consumption were registered, and an estimate of
their lifetime tobacco exposure was calculated as
pack-years.Pulmonary function testing
The FEV1 and forced vital capacity (FVC)
were measured with a 7 l dry wedge spirometer
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measurement consisted of at least two maximal
expiratory maneuvers from total lung capacity to
residual volume with a variation of less than 5% for
both FEV1 and FVC. The highest FEV1 and FVC were
used in the analyses. Data on pulmonary function
were also expressed as a percentage of the
predicted value (%pred), using prediction equations
based on age, sex, and height.17–19
Participants, who were taking medication for
asthma or allergy, were asked not to use an
antihistamine for at least 24 h, (astemizole for 6
weeks), an inhaled short-acting bronchodilator for
6 h, and a long-acting b2-agonist for 24 h before the
tests. They were allowed to continue use of any
corticosteroids they had been taking. In the event
of recent respiratory tract infection, the tests were
postponed for 6 weeks.Skin prick test
Skin prick test reactivity to common allergens was
tested, in duplicate, on the volar surface of the
forearm with standard dilutions (10 HEP) of the
allergens in 50% glycerol. The allergens used were
birch, grass, mugwort, horse, dog, cat, house dust
mite (HDM, Dermatophagoides pteronyssinus and
D. farinae) and two molds (Alternaria iridis and
Cladosporium herbarum). Histamine HCl, 10mg/
ml, in 50% glycerol was used as a positive control,
and a negative control (50% glycerol) was also
included. The reactions were read after 15–20min.
The reaction to each test was regarded as positive
if the mean wheal diameter ð½d1 þ d2  12Þ was at
least 3mm.20 Atopy was defined as a positive
reaction to at least one of the allergens.20Histamine challenge test
Airway responsiveness to inhaled histamine was
measured using the method described by Cockcroft
and colleagues.21 Aerosols of the test solution were
generated by a Wright nebulizer (Aerosol Products
Ltd., London, UK) with an output of 0.14ml/min.
Each aerosol was inhaled through the mouth by
tidal breathing for 2min. The first aerosol was
saline solution (0.9%), followed at 4-min intervals
by two-fold increasing concentrations of histamine
(0.075–16.0mg/ml). The response was measured
by the FEV1 1min after each inhalation. The test
was terminated when a decline of 20% or more in
FEV1 from the post-saline value occurred or after
the highest dose. The concentration of histamine
causing a 20% fall in FEV1 (PC20) was calculated by
linear interpolation from the individual log dose–response curve.22 A positive test was defined as a
PC20o16.0mg/ml histamine (AHR). Histamine re-
sponsiveness was also analyzed as dose–response
slope23; a constant of 3 was added to all dose–
response slopes to eliminate negative and zero
values.
Pregnant and lactating women were excluded
from the histamine challenge test.Bronchodilator reversibility
When the FEV1 following the histamine challenge
test had returned to 495% of the baseline value,24
a standard dose of b2-agonist (salbutamol) was
administered as a test for bronchodilator reversi-
bility. The FEV1 was measured after 15min, and
reversibility was calculated as DFEV1 [(FEV1max–
FEV1min)/FEV1max) 100, where FEV1max was the
highest measured FEV1; DFEV1X10% was defined as
a positive test (BRpos).Blood leukocyte counts
Venous blood was taken (before the histamine
challenge test), and following preparation in
accordance with standard techniques, the number
of eosinophil and neutrophil leukocytes were
counted.Statistical analysis
Data were analyzed using SPSS 10.0 (SPSS, Chicago,
IL, US). Differences between subjects with and
without a characteristic of interest, e.g. asthma
and airway hyperresponsiveness, were analyzed
using Student’s t-tests and nonparametric tests as
appropriate. Differences in proportions were tested
with w2 test. Potential correlation’s between
factors of interest were assessed by calculating
Pearson correlation coefficients.
Linear and logistic regression analysis were used,
as appropriate, to assess putative asthma-related
factors in relation to outcome variables of interest,
primarily CMH and asthma, and non-significant
variables were deleted by backward elimination.
A P value of o0.05 was considered significant.Results
A total of 624 subjects (66% of the sample) were
included in the analysis. Characteristics of the
sample are described in Table 1; of note, pre-
valence of atopy was higher in males, whereas
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Table 1 Characteristics of the population sample of young adults aged 19–29 years.
Males (n ¼ 279) Females (n ¼ 345)
Age (years) 24 (3) 24 (3)
Height (m) 1.82 (0.07) 1.68 (0.06)
BMI (kg/m2) 21.7 (3.6) 19.3 (3.8)
Current smokers 36.4% 43.8%
Pack-years 7.5 (5.0) 5.6 (4.1)
Asthma (MD) 9.7% 13.0%
Asthma (QC)
Current 8.6% 9.9%
Ever 14.0% 18.6%
CMH 6.9% 8.4%
Atopy 43.2% 23.0%
FEV1(%pred) 93.9 (11.2) 98.9 (12.9)
FEV1/FVC% 82.8 (6.9) 86.0 (6.4)
Mean values, SD in parentheses, (unless stated otherwise).
Abbreviations: BMI ¼ body mass index, CMH ¼ chronic mucus hypersecretion, MD ¼ doctor diagnosed, QC ¼ questionnaire
criteria; atopy ¼ positive skin prick test.
Chronic mucus hypersecretion: A marker of asthma in young adults? 1579females had higher proportion of smokers and
lower body mass index (BMI).Characteristics of participants with chronic
mucus hypersecretion
The overall prevalence of CMH was 7.7%; 8.4% in
females and 6.9% in males, respectively. Of the
subjects who reported CMH, 73% were current
smokers with no difference between males and
females. The prevalence of CMH among smokers
was 13.9% compared to 3.5% among non-smokers
(Po0:001). No significant differences in age or
height were found between participants with and
without CMH, but participants with CMH had
significantly lower BMI (P ¼ 0:01) and higher esti-
mated lifetime tobacco exposure (5.2 vs. 2.4 pack-
years, respectively; Po0:01) than the participants
who did not report CMH.
Furthermore, participants with CMH were also
more likely to report symptoms of rhinitis
(Po0:01), ever asthma (QC asthma; Po0:001),
current asthma (QC asthma; P ¼ 0:001), and doc-
tor-diagnosed asthma (MD asthma; P ¼ 0:001),
whereas no difference was found in the proportion
of subjects currently being treated with inhaled
corticosteroids (P40:5). In line with this, 50% and
53% of the participants reporting QC and MD
asthma, respectively, were current smokers com-
pared with a smoking rate of 38% among subjects
who did not report asthma (P ¼ 0:005).
Comparing the prevalence of airway hyperre-
sponsiveness (AHR; PC20o16mg/ml), atopy (pos.
skin prick test), and a positive b2-reversibility test(DFEV1410%) revealed no significant differences
between subjects with and without CMH.Factors associated with CMH
To investigate further the association between CMH
and symptoms and signs of airway disease, the data
were analyzed using multiple logistic regression
analysis with CMH as the outcome of interest. The
final model revealed that dyspnea at exertion, self-
reported asthma, lower BMI, higher lifetime tobac-
co exposure (pack-years), and lower FEV1/FVC
ratio significantly predicted the presence of CMH
(Table 2). The interaction between BMI and smoking
remained significant in the model, whereas inter-
action terms between the other variables included
in the analysis did not reach the level of statistical
significance. However, no significant association
was found between CMH and the following asthma-
related factors: airway responsiveness to inhaled
histamine (dose–response slope [Odds ratio (OR)
0.9, P40:5] or AHR [OR 1.4, P ¼ 0:4]), bronchodi-
lator reversibility [OR 0.8, P40:5], self-reported
rhinitis [OR1.3, P ¼ 0:3] or eczema [OR 0.9,
P40:5], atopy [OR 1.2, P40:5], FEV1 (%pred) [OR
1.0, P40:5], current therapy with inhaled corti-
costeroids [OR 1.1, P40:5], and B-eosinophil count
[OR 0.8, P40:5]. Substituting ever asthma (QC)
with current asthma (QC) or MD asthma did not
change these findings.
With current QC asthma as the outcome, the
presence of CMH had a sensitivity of 21%, a
specificity of 94%, and a predictive value of a
positive test of 25% for a diagnosis of asthma.
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Table 2 Multiple logistic regression analysis of predictors of chronic mucus hypersecretion (CMH; dependent
variable) in a population sample of young adults (n ¼ 624).
Variable OR 95% CI P
BMI 0.90 0.82–0.98 o 0.05
Dyspnoea at exertion 2.46 1.28–4.70 o 0.01
Asthma (QC) 2.45 1.30–4.64 o 0.01
FEV1/FVC 0.95 0.93–0.97 ¼ 0.02
Smoking (pack-years) 1.07 1.02–1.13 o 0.01
SmokingBMI 1.06 1.03–1.09 o0.01
Abbreviations: BMI ¼ body mass index, QC ¼ questionnaire criteria.
C.S. Ulrik et al.1580Substituting current QC asthma with MD asthma or
ever QC asthma did not substantially change these
findings.
Confining the analysis to participants who did not
report asthma showed that the presence of CMH
was significantly predicted only by self-reported
dyspnea at exertion (P ¼ 0:01) and number of pack-
years (P ¼ 0:01). The number of life-long non-
smoking participants reporting CMH was too small
to permit further analysis.
Smoking was significantly associated with CMH
(Po0:02) and dyspnea at exertion (Po0:05), but a
significant association was also found between
active smoking and higher blood-neutrophil count
(Po0:001).Discussion
In this general population study of young adults,
CMH was related to active smoking, and symptoms
and signs suggesting airflow limitation, whereas
no relationship was found between CMH and
objective markers of asthmatic airway lability,
incl. airway hyperresponsiveness. Our findings
therefore may suggest that CMH is an early marker
of smoking-related airways inflammation instead
of being useful as a marker of asthma in popula-
tion studies, as it in this epidemiological study
of young adults does not seem to identify
subjects with objective signs of asthmatic airways
inflammation.
CMH is reported by a substantial proportion of
never-smokers with asthma,1 not least in patients
with less well-controlled asthma. In these patients,
CMH may therefore be regarded as a marker for
poorly controlled airway inflammation. However, in
keeping with the present findings, a previously
published study by Sunyer et al.25 based on data
from the European Community Respiratory Health
Study (ECRHS), which includes subjects on averageolder than in the present study, has failed to
demonstrate an association between CMH and
airway hyperresponsiveness.25 Furthermore, Palla-
saho et al.26 have recently reported from a postal
questionnaire population study in Finland that CMH
is strongly related to smoking, whereas CMH was
not a significant predictor of asthma. So, although
up to 50% of subjects with asthma report CMH,26 it
appears that smoking-related CMH, which probably
reflects a different type of airway inflammation, is
so much more prevalent that self-reported CMH
does not reliably identify individuals with asthmatic
airway lability in population studies.
In epidemiological studies, questionnaire an-
swers about asthma, including MD asthma, have
generally been shown to have a high reliability,27–29
also when validated against airway hyperrespon-
siveness.30 However, questions including the term
asthma are influenced by differences in its report-
ing at the individual level and by differences in
diagnostic and treatment practices. In the present
study, the observed prevalence of self-reported
asthma was higher among smokers than among non-
smokers, whereas no difference between the two
groups was found in the proportion of subjects
currently treated with inhaled corticosteroids. So,
although most of the subjects reporting ever or MD
asthma are highly likely to actually be asthmatics,
our questionnaire may have identified a smaller
number of subjects where symptoms and signs of
smoking-related airway inflammation have been
misinterpreted—also by the treating physicians
—as asthma.
For years many clinicians and researchers have
regarded CMH as an innocent bystander of respira-
tory diseases, not least based on the early studies
by Fletcher and Peto.7,8 However, more recent
epidemiological studies looking at both asthma and
COPD have clearly demonstrated that CMH is an
independent risk factor for increased morbidity and
mortality.3,4,6,9,10,31 Furthermore, a very recent
study by Heijdra et al.32 has clearly demonstrated
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health status (St. George’s Respiratory Question-
naire) in smokers without COPD. The finding in the
present study of a prevalence of CMH of almost 8%
is therefore of major concern, and may have
important implications for the future burden of
respiratory morbidity in Danish adults, and prob-
ably also for adults in other countries. The
observed prevalence of CMH is comparable to
observations from other Nordic countries,26,33 but
an important difference is that the subjects in the
present study were younger, which most likely
reflect the disturbingly high smoking rates, not
least among females, in Denmark.
In general, smokers have lower BMI than non-
smokers. In the present study, the proportion of
smokers was higher among females than among
males, and the former group also had, on average,
lower BMI. One could therefore, as also suggested
by the significant interaction between BMI and
smoking, speculate if the observed association
between CMH and BMI in this young adult popula-
tion may reflect an interaction between smoking
and body weight instead of low BMI being a risk
factor for CMH.
In conclusion, this cross-sectional epidemiologi-
cal study has shown that not only is CMH prevalent
in young adults, it is also primarily related to other
symptoms and signs known to be associated with
smoking-related airway disease instead of being a
marker of asthmatic airway lability.Acknowledgements
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